TriSalus Life Sciences (TLSI) Change in Accured Expenses (2021 - 2026)

TriSalus Life Sciences' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $160000.0 for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 90.15% year-over-year to $160000.0 in Q1 2026; TTM through Mar 2026 was $556000.0, a 122.65% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 146.08% from the prior year.
• Change in Accured Expenses retreated to $160000.0 in Q1 2026 per TLSI's latest filing, from $692000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.4 million in Q4 2023 and bottomed at -$4.6 million in Q3 2023.
• The 5-year median for Change in Accured Expenses is $214728.0 (2022), against an average of $345882.4.
• Across the five-year window, Change in Accured Expenses jumped 1046.1% in 2022 and tumbled 1486.36% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $4.1 million in 2022, then surged by 30.69% to $5.4 million in 2023, then sank by 94.43% to $301000.0 in 2024, then soared by 129.9% to $692000.0 in 2025, then sank by 76.88% to $160000.0 in 2026.
• Per Business Quant, the three latest TLSI Change in Accured Expenses figures stand at $160000.0 (Q1 2026), $692000.0 (Q4 2025), and $1.5 million (Q3 2025).